Alyeska Investment Group
VKTX icon

Alyeska Investment Group’s Viking Therapeutics VKTX Stock Holding History

Alyeska Investment Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-52,362
Closed -$912K – 469
2018
Q3 		$912K Buy
+52,362
New +$623K 0.01% 355

Other funds holding VKTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Alyeska Investment Group's VKTX Position: Q4 2018 in Review

Alyeska Investment Group sold out of Viking Therapeutics (VKTX) in Q4 2018, closing a stake of 52,362 shares — an estimated $912K sold.

Alyeska Investment Group first reported a position in VKTX in Q3 2018 and held it in 1 quarter. The position peaked at $912K in Q3 2018. 168 funds tracked by Wall St. Rank hold VKTX as of Q4 2018.

  • Alyeska Investment Group reported no remaining Viking Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 52,362 Viking Therapeutics shares in Q4 2018, an estimated $912K.
  • Alyeska Investment Group first reported a position in Viking Therapeutics in Q3 2018 and held it in 1 quarter.
  • Alyeska Investment Group's Viking Therapeutics position peaked at $912K in Q3 2018.
  • 168 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2018.

Based on Alyeska Investment Group's 13F filing for Q4 2018, filed 14 Feb 2019.